Life stage

Frail elderly (sarcopenia, falls, recovery reserve)

The clinically frail subset of older adults — sarcopenia, falls, slow recovery from acute illness or surgery, reduced reserve — where the body's structural decline outpaces chronological aging.

What changes during this transition

Frailty is a clinical phenotype, not a synonym for 'old.' The canonical operational definition is the Fried phenotype (≥3 of: unintentional weight loss, exhaustion, weak grip, slow gait, low activity) validated in the Cardiovascular Health Study; about 7–12% of community-dwelling US adults ≥65 meet criteria, and another 35–50% are pre-frail. Sarcopenia — the loss of muscle mass and function defined operationally by EWGSOP2, AWGS, and SDOC consensus — is the tissue-level driver of physical frailty and an independent mortality predictor across the CHS, InCHIANTI, and SOF cohorts. The standard-of-care stack for sarcopenia and frailty is lifestyle-medicine first: resistance training (the only intervention with mortality-reduction signal in meta-analyses — Liu & Latham 2009 Cochrane Review and successors), protein intake floors of 1.0–1.2 g/kg actual body weight (1.2–1.5 g/kg in frail or post-surgical elderly, per PROT-AGE and ESPEN 2019), vitamin D repletion in confirmed deficiency, and active treatment of underlying conditions (CKD, CHF, COPD, depression, anemia, hypothyroidism). No peptide on this list approaches the evidence base of those four pillars. The peptide library is editorial-honest about this: the GH-axis cluster (CJC-1295, ipamorelin, tesamorelin) addresses the somatopause biology in theory; B12-methylcobalamin addresses a confirmed-deficiency contribution to falls and neuropathy that's routine to find in geriatric workup; MOTS-c sits at the mitochondrial-dysfunction theory of sarcopenia with no human frailty data yet. The unique safety-editorial angle in this trigger is **polypharmacy**. The median frail elderly adult takes 8–12 prescription medications; Beers Criteria 2023 and STOPP/START framework reconciliation is the single highest-yield intervention in the average patient. Layering a peptide on top of an already-complex regimen without medication review is the most common safety failure mode in this population, ahead of any peptide-specific mechanism concern. The companion editorial concern is falls risk: anything that worsens glycemic excursions (GH-axis peptides + sulfonylureas/insulin), causes orthostasis, or sedates compounds an already-stacked baseline.

Important caveat

Frailty deserves geriatrics or primary-care coordination — peptides do not substitute for resistance training, protein intake, vitamin D repletion, or treatment of underlying conditions. CRITICAL: polypharmacy review using Beers Criteria 2023 and STOPP/START is the highest-yield single intervention in the average frail elderly patient — do this BEFORE adding any peptide. Falls risk is the dominant adverse outcome (~30% of community-dwelling ≥65 fall annually; hip fracture one-year mortality is 20–30%); GH-axis peptides worsen insulin sensitivity and can interact with sulfonylureas/insulin to drive hypoglycemic falls. CKD and CHF overlap is the norm not the exception — both alter peptide PK and amplify fluid-retention concerns. Cancer-surveillance overlap matters: IGF-1 elevation in users with reduced screening adherence is editorially load-bearing. Acute illness, recent fall, or new functional decline warrants medical workup BEFORE any peptide consideration.

Peptides editorially relevant to frail elderly (sarcopenia, falls, recovery reserve)

4 peptides from the library — each evidence-tiered honestly.

Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.